Therapeutic Drug Monitoring-guided High-dose Infliximab for Infantile-onset Inflammatory Bowel Disease: A Case Series

Amit Assa, Lev Dorfman, Dror S. Shouval, Raanan Shamir, Shlomi Cohen

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Very early-onset inflammatory bowel disease (IBD) and specifically infantile-onset IBD patients, are characterized by high rates of extensive colonic involvement and decreased response rate to standard therapeutic regimens, including infliximab (IFX). We present a case series of 4 patients with infantile-onset IBD achieving clinical and biologic remission, after treatment with therapeutic drug monitoring (TDM)-guided accelerated high-dose IFX therapy. All patients were treated with accelerated high-dose IFX induction of up to 22 mg/kg. In 3 of these patients, accelerated high-dose IFX was used following failure of intensified standard dose induction. All patients achieved remission following re-induction.We suggest that children with infantile-onset IBD may require a TDM-guided accelerated high-dose IFX induction and maintenance treatment in order to achieve and maintain remission. Personalized approach in these patients is essential in order to prevent underdosing and to avoid inappropriate interpretation of treatment failure.

Original languageEnglish
Pages (from-to)516-520
Number of pages5
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume71
Issue number4
DOIs
StatePublished - 1 Oct 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Therapeutic Drug Monitoring-guided High-dose Infliximab for Infantile-onset Inflammatory Bowel Disease: A Case Series'. Together they form a unique fingerprint.

Cite this